Short answer
Parabilis Medicines Inc (PBLS) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Fiscal quarter ended September 30, 2026 results announced.
Parabilis Medicines Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Fiscal quarter ended September 30, 2026 results announced
- Press release includes Parabilis Medicines’ financial results and business highlights
- Exhibit 99.1 contains the detailed quarterly financial information and investor-relevant updates
Item EX-99.1 · Exhibit EX-99.1
- Zolucatetide desmoid-tumor data: 72.2% ORR at 32 weeks, 100% DCR across 46 patients, with no treatment-related discontinuations
- FDA-aligned PEDESTAL Phase 3 design, planned launch in first half 2027 and topline results anticipated in 2029
- Cash, equivalents and marketable securities $1.1B, expected to fund operations into 2030, reducing near-term financing risk
- Third-quarter revenue $2.1M, R&D expense $45.6M, and net loss $44.5M, reflecting accelerating clinical investment
- Revolution Medicines collaboration adds a combination study in previously treated RAS G12D-mutant MSS CRC, with costs shared equally
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Parabilis Medicines Inc 8-K filings
Get the next PBLS 8-K as it lands
Follow PBLS for push alerts, or ask the research agent what this filing means.